[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"angina-pectoris\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:angina-pectoris":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,51,94,118,145,166,189,223,249,277,293,320,344,369],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100545664","diagnostic-performance-of-artificial-intelligence-algorithms-in-prediction-of-acute-coronary-syndrome-based-on-white-blood-cell-properties-100545664",false,"NCT06384846","Diagnostic Performance of Artificial Intelligence Algorithms in Prediction of Acute Coronary Syndrome Based on White Blood Cell Properties","Diagnostic Performance of Artificial Intelligence Algorithms in Prediction of Acute Coronary Syndrome Based on White Blood Cell Properties (AI-ACS Trial)","Inclusion Criteria:\n\nGeneral inclusion criteria:\n\n* Male or female, aged 18 years or above.\n* Participant is willing and able to give informed consent for participation in the study.\n* Collection of WBC and hs-cTn data must be possible.\n* Criteria for timing of blood sampling for collection of WBC and hs-cTn data must be fulfilled, where applicable.\n\nCase cohort:\n\n* Suspicion of STEMI or NSTE-ACS according to current ESC guidelines.\n* Coronary angiography must have been performed within 72 hours after initial suspicion of ACS.\n* For patients qualifying for observation according to ESC guidelines, coronary angiography is not mandatory and time limits do not apply.\n* Confirmation of STEMI or NSTE-ACS by identification of a culprit lesion using coronary angiography; identical evaluation results by review board required.\n* For observation patients without coronary angiography, final discharge diagnosis is used to decide about the presence or absence of NSTEMI and\u002For ACS.\n* Criteria for timing of blood sampling for collection of WBC and hs-cTn data must be fulfilled.\n\nControl cohort:\n\n* Suspicion of STEMI or NSTE-ACS according to current ESC guidelines.\n* Coronary angiography must have been performed within 72 hours after initial suspicion of ACS.\n* No identification of a culprit lesion compatible with diagnosis of STEMI or NSTE-ACS during coronary angiography; identical evaluation results by review board required.\n* Criteria for timing of blood sampling for collection of WBC and hs-cTn data must be fulfilled.\n\nSupplementary cohort:\n\n* Subject presents without chest pain or with stable angina pectoris.\n* No indication for revascularization during coronary angiography; identical evaluation results by review board required.\n* Exclusion of elevated hs-cTn.\n* Criteria for timing of blood sampling for collection of WBC and hs-cTn data must be fulfilled.\n* Between initial blood sampling to collect WBC data and coronary angiography, the subject must not develop suspicion of ACS.\n\nRule-out cohort:\n\n* Suspicion of NSTE-ACS and NSTEMI rule-out according to current ESC guidelines, i.e. very low initial hs-cTn value, or low initial hs-cTn value and no significant 1-hour\u002F2-hour change in hs-cTn value.\n* No coronary angiography within 72 hours.\n* Criteria for timing of blood sampling for collection of WBC and hs-cTn data must be fulfilled.\n\nAll-comer cohort:\n\n* Subject presents to the emergency department with suspected ACS.\n* Clinical assessments, ECG, and measurements of hs-cTn, single or serial measurement, must be conducted according to ESC guidelines.\n* Collection of WBC data must be performed at initial blood withdrawal after admission to the emergency department.\n* Review board evaluations must confirm the presence or absence of a culprit lesion if coronary angiography was performed, as outlined for the case and control cohorts.\n\nExclusion Criteria:\n\n* Age below 18 years.\n* Subject refuses informed consent.\n* Collection of WBC and hs-cTn data is not possible.\n* Criteria for timing of blood sampling for collection of WBC and hs-cTn data cannot be fulfilled.\n* Suspicion of ACS occurs in subjects with no or stable angina pectoris any time between initial blood sampling and start of coronary angiography.",true,"ALL","18 Years",{"count":20,"type":21},3350,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate whether artificial intelligence (AI) algorithms can predict or exclude acute coronary syndrome (ACS) in adults using data generated by routine hematology testing. The main questions the study aims to answer are:\n\n* Can AI algorithms based on white blood cell (WBC) data predict or exclude ACS in subjects with suspected ACS?\n* Can erythrocyte (EC) and\u002For thrombocyte (TC) data, where available, improve or complement WBC-based AI prediction of ACS?\n* How does the diagnostic performance of the AI algorithms compare with high-sensitivity cardiac troponin (hs-cTn), and can the combination of AI algorithms and hs-cTn improve diagnostic performance?\n\nParticipants will undergo clinical assessment and blood testing as part of usual clinical care. Their previously generated clinical information, hematology data, and hs-cTn results will be used to train and test the AI algorithms. Participation in the study does not determine the indication for coronary angiography or treatment, and no additional study-specific treatments are performed.",[25,26,27,28,29],"Acute Coronary Syndrome","Angina Pectoris","NSTEMI - Non-ST Segment Elevation MI","STEMI - ST Elevation Myocardial Infarction","Unstable Angina (UA)",[31,32,33,34,35,36,37],"Artificial Intelligence","AI","hematology analyzer","ACS","white blood cell","Troponin","Machine learning","RECRUITING","2026-06-21",{"date":41,"type":42},"2026-06-24","ACTUAL",{"date":44,"type":42},"2024-02-01",{"date":46,"type":21},"2026-12-31",{"name":48,"class":49},"RobotDreams GmbH","INDUSTRY",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":80,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":50},"100612800","safety-and-clinical-performance-of-the-freesolve-resorbable-magnesium-scaffold-rms-system-in-subjects-with-coronary-artery-lesions-100612800","NCT07258290","Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions","Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (Freesolve) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries","BIOMAG-III","Clinical Inclusion Criteria:\n\n1. Subject is ≥ 18 years and ≤ 80 years of age\n2. Subject has provided written informed consent as approved by the Ethics Committee \u002F Institutional Review Board (IRB) of the respective clinical site prior to the study related procedures\n3. Subject is eligible for PCI according to the applicable guidelines\n4. Subject is an acceptable candidate for coronary artery bypass surgery\n5. Subjects with stable or unstable angina pectoris, documented silent ischemia\u002Fabnormal physiologic testing or hemodynamically stable non-ST elevation myocardial infarction (NSTEMI) patients without angiographic evidence of thrombus at target lesion\n\n   Note: STEMI patients may be eligible for the study for treatment of selected non-culprit lesions, if:\n   * Subject and target lesion(s) meet all inclusion and no exclusion criteria and consent occurs at least ≥ 72 hours after successful treatment of the culprit lesion(s) \\[lesion(s) causing the acute STEMI\\];\n   * Subject is hemodynamically stable with documented declining cardiac biomarkers;\n   * Target lesion(s) to be treated are not located in the culprit vessel(s) and are not culprit lesion(s)\n6. Subject is eligible for Dual Antiplatelet Therapy (DAPT) with aspirin plus either clopidogrel, prasugrel, ticagrelor or ticlopidine\n7. Documented left ventricular ejection fraction (LVEF) ≥ 30% within 6 months prior to or during the procedure (prior to randomization)\n8. Subject is willing and able to comply with protocol requirements, including completion of study visits for the duration of the study\n\nAngiographic Inclusion Criteria:\n\n1. Subjects with a maximum of two single de novo target lesions each in separate native coronary arteries\n2. Target vessel must have a reference diameter between 2.5-4.2 mm by operator visual estimation, which may be assisted by Quantitative Coronary Angiography (QCA) \u002F Intravascular Ultrasound (IVUS) \u002F Optical Coherence Tomography (OCT)\n3. Target lesion(s) must be ≤ 36 mm in length by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT, (or \\\u003C 20 mm for target lesion(s) to be treated with a study device \\\u003C 3.0 mm in diameter) and must be amenable to treatment with a single study device\n4. Target lesion stenosis ≥ 50% and \\\u003C 100% by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT. Target lesion stenosis \\\u003C 70% by visual estimation, should have clinical justification for treatment as per local standards.\n5. Target lesion must have a Thrombolysis in Myocardial Infarction (TIMI) flow ≥ 1\n\nClinical Exclusion Criteria:\n\n1. Subject is pregnant and\u002For breastfeeding or intends to become pregnant during the duration of the study\n2. Subject has clinical symptoms and\u002For electrocardiogram (ECG) changes consistent with STEMI \\\u003C 72 hours prior to the index procedure Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment\n3. Subject has undergone prior PCI within the target vessel during the last 12 months prior to the index procedure or prior PCI within a non-target vessel \\\u003C 72 hours prior to the index procedure\n4. Subject is on dialysis or has impaired renal function (serum creatinine \\> 2.5 mg\u002FdL or 221 µmol\u002FL, determined within 7 days prior to the index procedure)\n5. Subject has a known allergy to contrast medium that cannot be adequately premedicated, or any known allergy to aspirin, P2Y12 inhibitors, both heparin and bivalirudin, sirolimus, everolimus (or similar limus drugs), poly L-lactide, the scaffold material (magnesium, aluminum, tantalum), or Xience stent material (cobalt, chromium, tungsten, nickel, methacrylic polymer, and fluoropolymer)\n6. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are permitted) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted)\n7. Life expectancy less than 1 year\n8. Planned surgery or dental surgical procedure within 6 months after index procedure, unless DAPT can be maintained\n9. In the investigator's opinion subject will not be able to comply with the follow-up requirements\n10. Subjects under oral anticoagulation therapy (OAC) prior to index procedure unless DAPT + OAC (i.e., triple therapy) can be maintained for a minimum of 1 month\n11. Subject has had a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure\n12. Subject with active bleeding disorder, active coagulopathy, or any other reason, who is ineligible for DAPT\n13. Subject is currently participating or plans to participate in another study with an investigational device or an investigational drug\n14. Subject has known severe aortic or mitral valve stenosis\u002Finsufficiency or has previously undergone transcatheter aortic valve replacement (TAVR)\n\nAngiographic Exclusion Criteria:\n\n1. Target vessel has been previously treated and the target lesion is within 5 mm proximal or distal to the previously treated lesion\n2. Left main coronary artery disease\n3. Target lesion is totally occluded (100% stenosis)\n4. Thrombus in target vessel\n5. Future planned staged PCI either in target or non-target vessel\n6. Ostial target lesion within the left anterior descending (LAD), left circumflex (LCX), or right coronary artery (RCA) (within 5.0 mm of vessel origin)\n7. Target lesion involves a side branch ≥ 2.0 mm in diameter that requires a two-device strategy after pre-dilatation\n8. Target lesion is located in or supplied by an arterial or venous bypass graft\n9. Target lesion with excessive tortuosity proximal to or within the lesion based on visual estimation or heavily calcified target lesion which cannot be adequately pre-dilated by a non-compliant and\u002For cutting\u002Fscoring balloon as described in angiographic exclusion criteria 10\n10. Target lesion requires treatment with a device other than the non-compliant balloon and\u002For cutting\u002Fscoring balloon prior to scaffold\u002Fstent placement (including but not limited to atherectomy devices, intravascular lithotripsy, drug-coated balloons, etc.)\n11. Target vessel was treated with brachytherapy any time prior to the index procedure.\n12. Unsuccessful pre-dilatation, defined as residual stenosis \\> 20% (by visual estimation) and\u002For angiographic complications (e.g., distal embolization, side branch closure, flow-limiting dissections)","80 Years",{"count":61,"type":21},1859,"INTERVENTIONAL",[64],"NA","The objective of this study is to assess the safety and efficacy of the Freesolve resorbable magnesium scaffold (RMS) in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to the Xience coronary drug-eluting stent (DES) system",[67,68,69,70,71,72,73,74,75,76,77,78,79,25,26],"Coronary Disease","Heart Diseases","Cardiovascular Diseases","Arteriosclerosis","Arterial Occlusive Diseases","Vascular Diseases","Chest Pain","Pain","Neurologic Manifestations","Signs and Symptoms","Pathological Conditions, Signs and Symptoms","Coronary Artery Disease","Myocardial Ischemia",[81,82,83,84],"Resorbable Magnesium Scaffold","Sirolimus","RMS","Drug eluting absorbable metal scaffold","2026-06-15",{"date":87,"type":42},"2026-06-17",{"date":89,"type":42},"2026-06-11",{"date":91,"type":21},"2033-06",{"name":93,"class":49},"Teleflex",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":62,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100627491","self-expanding-coronary-sinus-reducer-for-treatment-of-symptomatic-coronary-microvascular-dysfunction-cmd-100627491","NCT07449325","Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)","Self-Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)","SERRA-I US","Inclusion criteria\n\n1. Older than 18 years of age.\n2. Left ventricular ejection fraction (LVEF) is greater than or equal to 25% within the 12 months before the index procedure. Note: The LVEF must be reassessed after any intervening myocardial infarction. The most recent LVEF assessment is used as the qualifying test for subjects with multiple assessments\n3. Greater than or equal to 30 days of persistent symptomatic coronary microvascular dysfunction (angina pectoris, or equivalent symptoms) (classified as CCS Grade II - IV angina, or NYHA Class 2 or 3 equivalent non-anginal functional impairment) despite optimal medical therapy, as determined by Investigator and confirmed by the Central Screening Committee. Note: Optimal medical management is defined as at least 2 anti-anginal medications or maximally tolerated medical therapy if less than 2 anti-anginal medications.\n4. CFR\\\u003C2.5 measured with continuous thermodilution within 30 days of index procedure. Note: CFR assessment may be completed during index procedure by Sponsor approved Investigators. RCA measurements are not permitted for this study.\n\n   Note: CFR should be measured in LAD or LCX if LAD is not feasible. RCA measurements are not permitted for this study\n5. Sustained angina (or equivalent symptoms) reported for at least 2 weeks leading up to the index procedure, as reported via the ORBITA-app.\n6. Willing and able to sign informed consent.\n7. Willing to comply with the specified follow-up evaluations.\n\n   Procedural Angiographic\u002FHemodynamic Inclusion Criteria:\n\n   The following will be assessed during the index procedure to confirm eligibility before an attempt at implantation. Note: CFR assessment may be completed during index procedure by Sponsor approved Investigators if not yet obtained in the prior 30 days (see inclusion criteria 4).\n8. Mean right atrial pressure ≤15 mmHg.\n9. The CS anatomy is suitable for implantation at the Investigator's discretion\n\nExclusion Criteria\n\n1. Significant obstructive epicardial disease (greater than 50% diameter stenosis) that can be treated with PCI or CABG as determined by Investigator and confirmed by the Central Screening Committee.\n2. Recent (less than 30 days before index procedure) troponin or CKMB positive acute coronary syndrome (NSTEMI or STEMI) with evidence of ischemia.\n\n   Note: subjects with an elevated troponin or CKMB without acute coronary syndrome may still be considered eligible.\n3. Extra-coronary contributory causes of angina- e.g., untreated hyperthyroidism, anemia (Hgb less than 9 g\u002FdL), uncontrolled hypertension (systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg despite medications), atrial fibrillation with a rapid ventricular response (consistently greater than 100 bpm despite medications) or other tachyarrhythmia, severe aortic stenosis, decompensated heart failure, hypertrophic cardiomyopathy with left ventricular outflow tract obstruction or asymmetric septal hypertrophy (concentric left ventricular hypertrophy is not an exclusion criterion).\n4. NYHA class IV or decompensated HF or hospitalization due to HF during the 90 days before the index procedure.\n5. Life-threatening rhythm disorders or any rhythm disorders that would require cardiac resynchronization therapy or lead placement in the coronary sinus.\n6. Severe chronic obstructive pulmonary disease (COPD) as indicated by a forced expiratory volume in one second (FEV1) of less than 1.0L or need for home daytime oxygen or regular oral steroids.\n7. Severe valvular heart disease (any valve).\n8. Moderate (TAPSE\\\u003C12) or severe RV dysfunction (TAPSE\\\u003C8) by echocardiography.\n9. A pacemaker electrode\u002Flead is present in the coronary sinus.\n10. Recent implantation of a new pacemaker or defibrillator leads with any electrode in the right atrium within 90 days of the index procedure.\n11. Chronic severe renal failure (estimated eGFR less than 30 mL\u002Fmin\u002F1.73m2 or equivalent) or subjects on chronic dialysis.\n12. Known allergy to titanium, nickel, platinum, tungsten, or known inability to tolerate contrast medium\n13. Any clinical condition that might interfere with the trial protocol or the subject's ability to be compliant with the trial protocol (e.g., active alcohol or illicit substance use, cognitive decline).\n14. Currently enrolled in another investigational device or drug trial that has not reached its primary endpoint or might clinically interfere with the current trial endpoints or procedures.\n15. Pregnant or planning pregnancy within the next 12 months (females of reproductive potential must have a negative pregnancy test within 7 days of the procedure).\n16. Part of a vulnerable population who, in the investigator's judgment, cannot give Informed Consent for reasons of incapacity, immaturity, adverse personal circumstances, or lack of autonomy.\n17. Inability to tolerate dual antiplatelet therapy for 6 months if not on a chronic oral anticoagulant, or inability to tolerate a P2Y12 inhibitor for at least 6 months if on a chronic oral anticoagulant.\n18. Comorbidities limiting life expectancy to less than one year.\n19. Currently hospitalized for definite or suspected COVID-19.",{"count":103,"type":21},30,[64],"VahatiCor's Coronary Sinus Reducer (A-FLUX) has been designed to improve angina or angina-like symptoms in patients with CMD. SERRA-I is an early feasibility study that evaluates the safety and clinical performance of the A-FLUX Reducer in this population.",[26,79,68,69,72,107],"Microvascular Angina","2026-05-14",{"date":110,"type":42},"2026-05-15",{"date":112,"type":21},"2026-04",{"date":114,"type":21},"2027-12",{"name":116,"class":49},"VahatiCor, Inc.",2,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":126,"targetDuration":4,"studyType":62,"phases":128,"briefSummary":129,"conditions":130,"keywords":134,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":144},"100599991","safety-and-clinical-performance-of-the-freesolve-resorbable-magnesium-scaffold-system-in-the-treatment-of-subjects-with-long-de-novo-lesions-100599991","NCT07091682","Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions","BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Resorbable MAGnesium Scaffold (Freesolve) in the Treatment of Subjects With Long de Novo Lesions in Native Coronary Arteries: BIOMAG-LL","BIOMAG-LL","Inclusion Criteria:\n\nClinical Inclusion Criteria\n\n1. Subject is ≥ 18 years and ≤ 80 years of age\n2. Subject has provided written informed consent as approved by the Independent Ethical Committee (IEC) or Institutional Review Board (IRB) of the respective clinical site prior to the study related procedures\n3. Subject is eligible for PCI according to the applicable guidelines\n4. Subject is an acceptable candidate for coronary artery bypass surgery\n5. Subjects with stable or unstable angina pectoris, documented silent ischemia\u002Fabnormal physiologic testing or hemodynamically stable non-ST elevation myocardial infarction (NSTEMI) patients without angiographic evidence of thrombus at target lesion\n\n   Note: STEMI patients may be eligible for the study for treatment of selected non-culprit lesions, if:\n   * Subject and target lesion(s) meet all inclusion and no exclusion criteria and consent occurs at least ≥ 72 hours after successful treatment of the culprit lesion(s) \\[lesion(s) causing the acute STEMI\\];\n   * Subject is hemodynamically stable with documented declining cardiac biomarkers;\n   * Target lesion(s) to be treated are not located in the culprit vessel(s) and are not culprit lesion(s)\n6. Subject is eligible for Dual Antiplatelet Therapy (DAPT) with aspirin plus either clopidogrel, prasugrel, ticagrelor, cangrelor or ticlopidine\n7. Documented left ventricular ejection fraction (LVEF) ≥ 30% within 6 months prior to or during the procedure (prior to enrollment)\n8. Subject is willing and able to comply with protocol requirements, including completion of study visits for the duration of the study\n\nAngiographic Inclusion Criteria\n\n1. Subjects with a maximum of two single de novo target lesions each in separate native coronary arteries\n2. Target vessel must have a reference diameter between 2.7-4.2 mm by visual estimation, which may be assisted by Quantitative Coronary Angiography (QCA) \u002F Intravascular Ultrasound (IVUS) \u002F Optical Coherence Tomography (OCT)\n3. Target lesion must be \\>28 mm and ≤ 38 mm in length by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT, and should be amenable to treatment with a single study device\n4. Target lesion stenosis ≥ 50% and \\\u003C 100% by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT. Target lesion stenosis \\\u003C 70% by visual estimation, should have clinical justification for treatment as per local standards.\n5. Target lesion must have a Thrombolysis In Myocardial Infarction (TIMI) flow ≥1\n\nExclusion Criteria:\n\nClinical Exclusion Criteria\n\n1. Subject is pregnant and\u002For breastfeeding or intends to become pregnant during the duration of the study\n2. Subject has clinical symptoms and\u002For electrocardiogram (ECG) changes consistent with STEMI \\\u003C 72 hours prior to the index procedure.\n\n   Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment.\n3. Subject has undergone prior PCI within the target vessel during the last 12 months prior to the index procedure or prior PCI within a non-target vessel \\\u003C72 hours prior to the index procedure (time window is defined as the time from the end of previous intervention to the start of index procedure)\n4. Subject is on dialysis or with impaired renal function (serum creatinine \\> 2.5 mg\u002FdL or 221 µmol\u002FL, determined within 72 hours prior to the index procedure)\n5. Subject has a known allergy to contrast medium that cannot be adequately premedicated, or any known allergy to aspirin, P2Y12 inhibitors, both heparin and bivalirudin, sirolimus (or similar limus drugs), poly L-lactide, the scaffold material (magnesium, aluminum, tantalum)\n6. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are permitted) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted)\n7. Life expectancy less than 1 year\n8. Planned surgery or dental surgical procedure within 6 months after index procedure, unless DAPT can be maintained.\n9. In the investigator's opinion subject will not be able to comply with the follow-up requirements\n10. Subjects under oral anticoagulation therapy (OAC) prior to index procedure unless DAPT + OAC (i.e. triple therapy) can be maintained for a minimum of 1 month\n11. Subject has had a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure .\n12. Subject with active bleeding disorder, active coagulopathy, or any other reason, who is ineligible for DAPT.\n13. Subject is currently participating or plans to participate in another study with an investigational device or an investigational drug\n\nAngiographic Exclusion Criteria:\n\n1. Target vessel has been previously treated and the target lesion is within 5 mm proximal or distal to the previously treated lesion.\n2. Left main coronary artery disease\n3. Target lesion was totally occluded (100% stenosis)\n4. Thrombus in target vessel\n5. Future planned staged PCI either in target or non-target vessel\n6. Ostial target lesion within the left descending (LAD), left circumflex (LCx), or right coronary artery (within 5.0 mm of vessel origin)\n7. Target lesion involves a side branch ≥ 2.0 mm in diameter that requires a two-device strategy after pre-dilatation.\n8. Target lesion is located in or supplied by an arterial or venous bypass graft.\n9. Target lesion with excessive tortuosity proximal to or within the lesion based on visual estimation or heavily calcified target lesion which cannot be adequately pre-dilated by a non-compliant and\u002For cutting\u002Fscoring balloon as described in angiographic exclusion criteria 10.\n10. The target lesion requires treatment with the device other than the non-compliant balloon and\u002For cutting\u002Fscoring balloon prior to scaffold placement (including but not limited to atherectomy devices, intravascular lithotripsy, drug-coated balloons etc.)\n11. Target vessel was treated with brachytherapy any time prior to the index procedure.\n12. Unsuccessful pre-dilatation, defined as residual stenosis \\> 20% (by visual estimation) and \u002F or angiographic complications (e.g. distal embolization, side branch closure, flow-limiting dissections)",{"count":127,"type":21},100,[64],"The study objective is the assessment of safety and clinical performance of Freesolve 35- and 40-mm in de novo coronary artery lesions up to 38 mm length.",[78,131,79,132,133,26],"Atherosclerosis of Coronary Artery","Ischemic Heart Disease","Acute Coronary Syndromes",[81,82,83,84],"2025-11-20",{"date":137,"type":42},"2025-11-21",{"date":139,"type":42},"2025-02-18",{"date":141,"type":21},"2031-06",{"name":143,"class":49},"Biotronik AG",8,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":153,"targetDuration":4,"studyType":62,"phases":154,"briefSummary":155,"conditions":156,"keywords":158,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":50},"100480764","safety-and-clinical-performance-of-the-freesolve-resorbable-magnesium-scaffold-system-100480764","NCT05540223","Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System","BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (Freesolve®) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries: BIOMAG-II: A Randomized Controlled Trial","BIOMAG-II","Clinical Inclusion Criteria:\n\n1. Subject is ≥ 18 years and ≤ 80 years of age\n2. Subject has provided written informed consent as approved by the Independent Ethical Committee (IEC) or Institutional Review Board (IRB) of the respective clinical site prior to the study related procedures\n3. Subject is eligible for PCI according to the applicable guidelines\n4. Subject is an acceptable candidate for coronary artery bypass surgery\n5. Subjects with stable or unstable angina pectoris, documented silent ischemia\u002Fabnormal physiologic testing or hemodynamically stable non-ST elevation myocardial infarction (NSTEMI) patients without angiographic evidence of thrombus at target lesion\n\n   Note: STEMI patients may be eligible for the study for treatment of selected non-culprit lesions, if:\n   * Subject and target lesion(s) meet all inclusion and no exclusion criteria and consent occurs at least ≥ 72 hours after successful treatment of the culprit lesion(s) \\[lesion(s) causing the acute STEMI\\];\n   * Subject is hemodynamically stable with documented declining cardiac biomarkers;\n   * Target lesion(s) to be treated are not located in the culprit vessel(s) and are not culprit lesion(s)\n6. Subject is eligible for Dual Antiplatelet Therapy (DAPT) with aspirin plus either clopidogrel, prasugrel, ticagrelor or ticlopidine\n7. Documented left ventricular ejection fraction (LVEF) ≥ 30% within 6 months prior to or during the procedure (prior to randomization)\n8. Subject is willing and able to comply with protocol requirements, including completion of study visits for the duration of the study\n\nAngiographic Inclusion Criteria:\n\n1. Subjects with a maximum of two single de novo target lesions each in separate native coronary arteries\n2. Target vessel must have a reference diameter between 2.5-4.2 mm by visual estimation, which may be assisted by Quantitative Coronary Angiography (QCA) \u002F Intravascular Ultrasound (IVUS) \u002F Optical Coherence Tomography (OCT)\n3. Target lesion must be ≤28mm in length by operator visual estimation, which may be assissted by QCA \u002F IVUS \u002F OCT, (or \\\u003C 20 mm for target lesion(s) to be treated with a study device \\\u003C 3.0 mm in diameter) and should be amenable to treatment with a single study device\n4. Target lesion stenosis ≥ 50% and \\\u003C 100% by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT. Target lesion stenosis \\\u003C 70% by visual estimation, should have clinical justification for treatment as per local standards.\n5. Target lesion must have a Thrombolysis In Myocardial Infarction (TIMI) flow ≥1\n\nClinical Exclusion Criteria:\n\n1. Subject is pregnant and\u002For breastfeeding or intends to become pregnant during the duration of the study\n2. Subject has clinical symptoms and\u002For electrocardiogram (ECG) changes consistent with STEMI \\\u003C 72 hours prior to the index procedure.\n\n   Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment.\n3. Subject has undergone prior PCI within the target vessel during the last 12 months prior to the index procedure or prior PCI within a non-target vessel \\\u003C72 hours prior to the index procedure if successful and uncomplicated\n4. Subject is on dialysis or with impaired renal function (serum creatinine \\> 2.5 mg\u002FdL or 221 µmol\u002FL, determined within 72 hours prior to the index procedure)\n5. Subject has a known allergy to contrast medium that cannot be adequately premedicated, or any known allergy to aspirin, P2Y12 inhibitors, both heparin and bivalirudin, sirolimus, everolimus (or similar limus drugs), poly L-lactide, the scaffold material (magnesium, aluminium, tantalum), or Xience stent material (cobalt, chromium, tungsten, nickel, -methacrylic polymer, and fluoropolymer)\n6. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are permitted) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted)\n7. Life expectancy less than 1 year\n8. Planned surgery or dental surgical procedure within 6 months after index procedure, unless DAPT can be maintained\n9. In the investigator's opinion subject will not be able to comply with the follow-up requirements\n10. Subjects under oral anticoagulation therapy (OAC) prior to index procedure unless DAPT + OAC (i.e. triple therapy) can be maintained for a minimum of 1 month\n11. Subject has had a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure\n12. Subject with active bleeding disorder, active coagulopathy, or any other reason, who is ineligible for DAPT\n13. Subject is currently participating or plans to participate in another study with an investigational device or an investigational drug\n\nAngiographic Exclusion Criteria:\n\n1. Target vessel has been previously treated and the target lesion is within 5 mm proximal or distal to the previously treated lesion\n2. Left main coronary artery disease\n3. Target lesion was totally occluded (100% stenosis)\n4. Thrombus in target vessel\n5. Future planned staged PCI either in target or non-target vessel\n6. Ostial target lesion within the left descending (LAD), left circumflex (LCx), or right coronary artery (within 5.0 mm of vessel origin)\n7. Target lesion involves a side branch ≥ 2.0 mm in diameter that requires a two-device strategy after pre-dilatation\n8. Target lesion is located in or supplied by an arterial or venous bypass graft\n9. Target lesion with excessive tortuosity proximal to or within the lesion based on visual estimation or heavily calcified target lesion which cannot be adequately pre-dilated by a non-compliant and\u002For cutting\u002Fscoring balloon as described in angiographic exclusion criteria 10.\n10. The target lesion requires treatment with the device other than the non-compliant balloon and\u002For cutting\u002Fscoring balloon prior to scaffold\u002Fstent placement (including but not limited to atherectomy devices, intravascular lithotripsy, drug-coated balloons etc.)\n11. Target vessel was treated with brachytherapy any time prior to the index procedure.\n12. Unsuccessful pre-dilatation, defined as residual stenosis \\> 20% (by visual estimation) and \u002F or angiographic complications (e.g. distal embolization, side branch closure, flow-limiting dissections)",{"count":61,"type":21},[64],"The objective of this study is to assess the safety and efficacy of the Freesolve in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to a contemporary drug eluting stent (DES).",[78,157,79,132,25,26],"Atherosclerosis, Coronary",[81,82,83,84],"2025-11-18",{"date":137,"type":42},{"date":162,"type":42},"2024-05-13",{"date":164,"type":21},"2032-02",{"name":143,"class":49},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":50},"100542900","clinical-evaluation-of-radiation-reduction-for-optimized-safety-100542900","NCT06348875","Clinical Evaluation of Radiation Reduction for Optimized Safety","CERROS","Inclusion Criteria:\n\n* Referred for clinically indicated coronary angiography\n* ≥18 years of age\n* Not pregnant\n* English speaking\n* Not imprisoned\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Hemodynamically or electrically unstable.\n* Indication for coronary angiography is emergent, including ST-segment elevation myocardial infarction\n* History of coronary artery bypass grafting\n* An eGFR \\\u003C60\n* Pregnant or lactating\n* A BMI of 45 or greater\n* Any other factor that the investigator feels would put the patient at increased risk or otherwise make the patient unsuitable for participation in the protocol",{"count":174,"type":21},50,"The primary objective of this study is to determine whether a reduced radiation protocol (RRP) in which angiograms are acquired at ultralow radiation doses and then processed using spatiotemporal enhancement software can produce similar quality angiographic images as compared with standard techniques.",[78,177,67,178,26,73],"Myocardial Infarction","Coronary Stenosis","NOT_YET_RECRUITING","2025-11-12",{"date":182,"type":42},"2025-11-13",{"date":184,"type":21},"2026-02-15",{"date":186,"type":21},"2026-07-15",{"name":188,"class":49},"Angiowave Imaging",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":62,"phases":199,"briefSummary":200,"conditions":201,"keywords":204,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":50},"100477065","coronary-sinus-reducer-implantation-in-patients-with-ischaemia-and-non-obstructed-coronary-arteries-and-coronary-microvascular-dysfunction-100477065","NCT05492110","Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microvascular Dysfunction.","REducing Microvascular Dysfunction in Patients With Angina, Ischaemia and unobstructED coronarY Arteries - a PILOT Study","REMEDY-PILOT","Inclusion Criteria:\n\n1. Age \\>18 years\n2. Ongoing symptomatic angina, CCS Class II-IV, for ≥3 months despite background treatment with at least two anti-anginal drug at the maximal tolerated dose.\n3. Patients willing to consider no change in anti-anginal drug treatment for the duration of their participation in the trial.\n4. Unobstructed coronary arteries with ≤50% epicardial stenoses demonstrated on coronary angiography.\n5. Stress-induced hypoperfusion on CMR (Global MPR ≤ 2.2).\n6. Willingness to comply with the specified follow-up evaluation and to be contactable during the period of the trial.\n7. Understands the nature of the trial procedures and provides written informed consent.\n\nExclusion Criteria:\n\n1. Epicardial CAD in a main coronary artery (stenoses \\>50%, RFR≤0.92 or FFR≤0.80), coronary artery bypass grafting, or myocardial infarction (MI).\n2. Previous PCI within 6 months\n3. PCI with stent insertion for acute MI or chronic total occlusion (CTO)\n4. Abnormal coronary sinus anatomy (tortuosity, aberrant branch, persistent left superior vena cava)\n5. Coronary sinus diameter at site of implant \\\u003C9.5mm or \\>13mm\n6. Mean right atrial pressure \\\u003C15mmHg at time of implantation\n7. Any structural heart disease including left ventricular hypertrophy; cardiomyopathy; severe valvular heart disease; previous valve replacement; myocardial bridge on angiography; LVEF\\\u003C45% by CMR.\n8. Clinically or angiographically diagnosed coronary vasospasm\n9. Previous hospitalisation for decompensated heart failure\n10. Pacemaker or defibrillator electrode in the right atrium, right ventricle or coronary sinus\n11. Documented arrhythmia requiring planned implantation of a permanent pacemaker or defibrillator\n12. Chronic kidney disease (creatinine \\>200 micromol\u002FL; established on renal replacement therapy; functioning renal transplant)\n13. Haemoglobin \\\u003C80g\u002FL\n14. Contraindications to receiving dual antiplatelet therapy\n15. Severe chronic obstructive pulmonary disease (FEV1 \\\u003C55% predicted)\n16. Moribund patients with life expectancy \\\u003C 1year\n17. Known allergy to nickel or steel\n18. Current enrolment in another investigational device or drug trial\n19. Contraindications to CMR or receiving intravenous adenosine\n20. Pregnancy",{"count":198,"type":21},54,[64],"To demonstrate the feasibility and efficacy of the CS Reducer for the treatment of patients with ischaemia and non-obstructed coronary arteries (INOCA) and coronary microvascular dysfunction (CMD) and through a nested mechanistic substudy investigate the physiological responses in the coronary microcirculation responsible for changes in myocardial perfusion.",[202,107,203,67,26],"Refractory Angina","Microvascular Coronary Artery Disease",[205,206,207,208,209,210,211,212],"Angina pectoris","Refractory angina","Microvascular angina","Coronary microvascular dysfunction","Coronary sinus reducer","Chest pain","Coronary disease","Myocardial ischaemia","2025-03-31",{"date":215,"type":42},"2025-04-03",{"date":217,"type":42},"2023-04-17",{"date":219,"type":21},"2026-03-06",{"name":221,"class":222},"Imperial College London","OTHER",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":62,"phases":233,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":50},"100548733","phase-2-efficacy-of-targeted-medical-therapy-in-angina-and-nonobstructive-coronary-arteries-100548733","NCT06424834","Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries","A Randomized Controlled Study of Targeted Medical Therapy Versus Placebo for Angina and Non- Obstructive Coronary Arteries: The MVP-ANOCA Study","MVP-ANOCA","Inclusion Criteria:\n\n* All patients with stable angina referred to the Stanford University Hospital cardiac catheterization laboratory for clinically indicated coronary function testing are eligible for inclusion into the study.\n\nSpecific inclusion criteria for randomization:\n\n* Absence of significant epicardial coronary artery disease on angiography\n* Fractional flow reserve \\> 0.80\n\nAnd ≥ 1 of the following:\n\n* Epicardial coronary spasm on acetylcholine testing\n* Microvascular spasm on acetylcholine testing\n* Coronary flow reserve \\\u003C 2.5\n* Index of microcirculatory resistance ≥ 25\n* Myocardial bridge on intravascular ultrasound with dobutamine resting full-cycle ratio ≤ 0.76\n\nExclusion Criteria:\n\n* Acute coronary syndrome less than one week prior to enrolment\n* Cardiomyopathy\n* Contraindications to beta-blockers or calcium channel blockers\n* Baseline systolic blood pressure \\\u003C 95 mmHg\n* Baseline heart rate \\\u003C 55 bpm",{"count":232,"type":21},150,[234,235],"PHASE2","PHASE3","The goal of this clinical trial is to learn if targeted medical therapy will improve symptoms and quality of life in patients with angina and non-obstructive coronary arteries compared to placebo, after the underlying cause of the chest pain has been ascertained by coronary function testing.\n\nParticipants will be treated with either medications that target the underlying cause of their chest pain or placebo for 4 weeks after a drug titration phase of 1-3 weeks. They will be asked to complete a series of questionnaires to evaluate their quality of life at the beginning and end of the study.",[26,107,238,239],"Vasospastic Angina","Myocardial Bridge of Coronary Artery","2024-11-26",{"date":242,"type":42},"2024-11-27",{"date":244,"type":42},"2024-10-10",{"date":246,"type":21},"2026-12",{"name":248,"class":222},"Stanford University",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":256,"targetDuration":258,"studyType":22,"phases":4,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":50},"100521900","complex-registry---a-prospective-cohort-study-to-describe-the-management-and-outcomes-of-patients-presenting-with-complex-and-calcified-coronary-artery-disease-100521900","NCT06075602","COMPLEX Registry - a Prospective COhort Study to Describe the Management and Outcomes of Patients Presenting with CompLEX and Calcified Coronary Artery Disease","COMPLEX","Inclusion Criteria:\n\n* Subject \\>18 years of age\n* Individuals presenting with chronic, complex and\u002For calcified CAD and requiring PCI or CABG\n* Complex coronary artery disease \u002F lesions must include at least one of the following attributes:\n* Long and\u002F or heavily calcified coronary lesions\n* In-stent restenosis\n* Chronic total occlusions (CTO)\n* Left main lesions\n* Bifurcation lesions\n* Bypass graft lesions\n* Small vessel disease \u002F coronary microvascular dysfunction (e.g. not amenable to PCI)\n* Subjects must be willing to sign a patient informed consent (PIC) or must have signed the General Consent (GK).\n\nExclusion Criteria:\n\nThe presence of any one of the following exclusion criteria will lead to exclusion of the patient.\n\n* Patient is \\\u003C18 years of age\n* Patient unwilling or unable to provide informed consent\n* Patients with no complex and calcified CAD",{"count":257,"type":21},5000,"10 Years","The purpose of the COMPLEX Registry is to prospectively and retrospectively collect baseline, clinical and procedural data of patients who have undergone PCI or CABG for complex and\u002F or calcified chronic CAD, irrespective of clinical presentation as well as to prospectively collect data about their clinical outcomes. The outcomes will be compared in different clinical subgroups (e.g. PCI vs. CABG). The impact of current PCI techniques\u002F devices, but also CABG strategies in different clinical settings and coronary artery lesions on cardiovascular outcomes will be assessed.",[67,78,261,262,263,264,26,265,266,267],"Coronary Restenosis","Coronary Arteriosclerosis","Coronary Artery Calcification","Stable Chronic Angina","Angina, Stable","Angina, Unstable","Stent Thrombosis","2024-10-27",{"date":270,"type":42},"2024-10-29",{"date":272,"type":42},"2021-11-01",{"date":274,"type":21},"2031-12-31",{"name":276,"class":222},"Luzerner Kantonsspital",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":284,"targetDuration":258,"studyType":22,"phases":4,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":292,"locationsCount":50},"100438392","siroop-registry---a-prospective-registry-study-to-evaluate-the-outcomes-of-coronary-artery-disease-patients-treated-with-sirolimus-or-paclitaxel-eluting-balloon-catheters-100438392","NCT04988685","SIROOP Registry - A Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated With SIROlimus Or Paclitaxel Eluting Balloon Catheters","SIROOP","Inclusion Criteria:\n\n* Subject \\>18 years of age\n* Patients with significant acute or chronic coronary de-novo lesions or ISR lesions requiring treatment using PCI\n* Treatment with at least one DCB (device choice at the operator's discretion) In case of a patient with lesions treated at different procedural time, lesions will be separately collected and documented\n* Subjects must be willing to sign a patient informed consent (PIC) or must have signed the General Consent (GK).\n\nExclusion Criteria:\n\n* Patient is \\\u003C18 years of age\n* Patient unwilling or unable to provide informed consent\n* pregnancy and lactation\n* Indication for surgical revascularization",{"count":285,"type":21},2000,"The purpose of the SIROOP Registry is to retrospectively and prospectively collect baseline, clinical and procedural characteristics of patients who have undergone PCI and are treated with either currently available sirolimus or paclitaxel coated DCBs (see Table 1), irrespective of clinical presentation as well as to prospectively collect data about their clinical outcomes. Outcomes will be compared in different clinical subgroups. The impact of current DCBs in different clinical settings and coronary artery lesions on cardiovascular outcomes will be assessed.",[67,78,261,262,263,264,26,265,266,267],{"date":270,"type":42},{"date":290,"type":42},"2021-06-01",{"date":274,"type":21},{"name":276,"class":222},{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":303,"conditions":304,"keywords":305,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":50},"100558002","appropriateness-of-angioplasty-in-patients-with-chronic-coronary-syndromes-100558002","NCT06545448","Appropriateness of Angioplasty in Patients With Chronic Coronary Syndromes","Appropriateness of Angioplasty in Patients With Chronic Coronary Syndromes in a Cardiology Reference Hospital - The RIGHT-PCI Study","RIGHT-PCI","Inclusion Criteria:\n\n* All patients within the age range who underwent elective PCI defined as a procedure indicated in an outpatient scenario or an inpatient in a non-acute setting when the Heart Team was called to evaluate the patient and agreed with the indication for PCI\n\nExclusion Criteria:\n\n* History of acute coronary syndrome \\\u003C 30 days of the referral for PCI",{"count":302,"type":21},1875,"Percutaneous coronary intervention (PCI) has dramatically changed the treatment of obstructive coronary artery disease patients. PCI is indicated in patients with chronic coronary syndrome (CCS) symptoms unresponsive to optimized medical therapy. The American College of Cardiology Foundation and partners developed in 2009 - and updated them in May 2017 - the appropriateness criteria for PCI to support the rational use of PCI in chronic patients and to provide patients with high-quality cardiovascular care. Since then, these criteria have been applied to guide physicians and serve as metrics of the quality of care based on the best available scientific evidence. Countries like the United States and Japan already have robust studies on the topic with important repercussions on clinical practice. In Brazil, to date, there are no studies on the adequacy of PCIs in patients with CCS.",[78,26],[306,205,307,308,309,310],"Coronary artery disease","Angioplasty","Appropriateness","Prognosis","Treatment","2024-08-05",{"date":313,"type":42},"2024-08-09",{"date":315,"type":42},"2017-12-01",{"date":317,"type":21},"2025-12-31",{"name":319,"class":222},"University of Sao Paulo General Hospital",{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":50},"100243526","high-sensitivity-troponin-t-plasma-levels-in-patients-with-aortic-stenosis-tyrolean-aortic-stenosis-study-2-100243526","NCT02448485","High-Sensitivity Troponin T Plasma Levels in Patients With Aortic Stenosis (Tyrolean Aortic Stenosis Study-2)","High-Sensitivity Troponin T Plasma Levels in Patients With Aortic Stenosis","TASS-2","Inclusion Criteria:\n\n* aortic stenosis detected by echocardiography \u002F invasively\n\nExclusion Criteria:\n\n* acute coronary syndrome\n* endocarditis",{"count":329,"type":21},10000,"TASS-2 (Tyrolean Aortic Stenosis Study-2) aims to characterize the clinical value of minimally elevated troponin T plasma levels both in patients with asymptomatic and symtomatic aortic stenosis.",[332,333,334,26],"Aortic Stenosis","Heart Failure","Syncope","2024-07-31",{"date":337,"type":42},"2024-08-01",{"date":339,"type":42},"2015-06",{"date":341,"type":21},"2025-10",{"name":343,"class":222},"Medical University Innsbruck",{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":351,"enrollmentInfo":352,"targetDuration":4,"studyType":62,"phases":354,"briefSummary":355,"conditions":356,"keywords":357,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":50},"100536533","impact-of-coronary-sinus-flow-reducer-on-coronary-microcirculation-and-myocardial-ischemia-100536533","NCT06266065","Impact of Coronary Sinus Flow Reducer on Coronary Microcirculation and Myocardial Ischemia","Impact of Coronary Sinus Flow Reducer on Coronary Microcirculation and Myocardial Ischemia in Patients With Refractory Angina Pectoris","Inclusion Criteria:\n\n* Patients with coronary artery disease and refractory angina pectoris who are ineligible for coronary revascularization\n* Signed informed consent\n\nExclusion Criteria:\n\n* Severely reduced systolic ejection fraction of the left ventricle (EF \\\u003C 35 %)\n* Severe renal impairment (eGFR \\\u003C 30ml\u002Fmin\u002F1.73m2)\n* Severe chronic obstructive pulmonary disease (GOLD D)\n* Contraindication for application of papaverine or regadenoson","90 Years",{"count":353,"type":21},25,[64],"The increasing number of coronary revascularization procedures, coupled with improvements in drug therapy, has significantly extended the lifespan of patients with coronary artery disease (CAD). However, there remains a significant number of CAD patients who experience disability due to chronic refractory angina pectoris. These patients typically have severe diffuse CAD and are not candidates for further revascularization involving surgical coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI).\n\nThe installation of a coronary sinus reducer (CSR) represents a new option for percutaneous treatment of patients with refractory angina pectoris who are not suitable for surgical or percutaneous revascularization. The CSR device is designed as an hourglass-shaped stent that is positioned transcatheterally in the distal part of the coronary sinus. This increases intramyocardial venous pressure, which is believed to lead to a more favorable perfusion ratio between the ischemic subendocardial and non-ischemic subepicardial myocardium. Previous research has demonstrated that the implantation of CSR is a safe and relatively straightforward procedure. However, broader implementation and better patient selection are still limited by the fact that the exact mechanism of action remains controversial. It has not been determined why some patients have better outcomes compared to others with seemingly similar coronary artery disease. It is known that patients with atherosclerotic changes in the epicardial coronary arteries also have a certain degree of coronary microcirculation disease (the coronary vascular bed encompassing vessels with a diameter \\\u003C 200 μm), which cannot be assessed through standard coronary angiography. This study aims to assess changes in coronary microcirculation after the implantation of CSR by measuring coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) before and 6 months after the procedure. Furthermore, our goal is to associate these changes with clinical symptoms and myocardial ischemia.",[78,26],[358,79,359],"Coronary Sinus Reducer","Coronary Microcirculation","2024-03-05",{"date":362,"type":42},"2024-03-06",{"date":364,"type":42},"2024-02-27",{"date":366,"type":21},"2026-06",{"name":368,"class":222},"Clinical Hospital Centre Zagreb",{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":62,"phases":378,"briefSummary":379,"conditions":380,"keywords":382,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":394,"locationsCount":50},"100429562","effectiveness-of-ecp-therapy-in-stable-angina-pectoris-patients-100429562","NCT04873687","Effectiveness of ECP Therapy in Stable Angina Pectoris Patients","Effectiveness of External Counter Pulsation (ECP) Therapy in Stable Angina Pectoris Patients; a Proof of Principal Clinical Trial","Inclusion Criteria:\n\n* Age \\>= 18 years old\n* Diagnosed with stable angina pectoris\n* Anatomic vessel disease (VD) lesion with 2VD\u002F3VD\n* Indicated for CABG and in waiting list of CABG procedure; or refuse for CABG and choose medical therapy only; or patients who are decided by the responsible doctor for medical treatment alone because of the high risks of CABG surgery.\n* Not planned to urgent CABG\n* Minimum optimal medical therapy within 2 weeks\n* Able and willing to sign informed consent and comply with study procedures\n* The patient lives in Bandung City and its neighborhood\n* Retired patient; or not actively working during working hours; or willing to take the time to participate in research.\n\nExclusion Criteria:\n\n* Congestive Heart Failure\n* Chronic heart failure with Functional Class NYHA III - IV\n* LVEF \\\u003C35%\n* Unprotected left main stenosis \\>50%\n* Blood pressure \\>180\u002F110mmHg\n* Acute coronary syndrome\n* Acute Heart Failure\n* Severe aorta regurgitation\n* Malignant arrhythmia\n* Atrial fibrillation\n* Premature ventricular complex\n* Peripheral occlusive artery disease\n* Phlebitis\n* Deep vein thrombosis\n* Hemorrhagic diathesis\n* Severe chronic kidney disease\n* Aortic aneurysm\n* Abdominal aneurysm\n* Osteoarthritis\n* Low back pain\n* Pregnancy\n* Registered as other clinical study participant",{"count":377,"type":21},84,[64],"External Counterpulsation (ECP) is a non-invasive therapy using pressured cuff that is performed on patients with refractory stable angina pectoris to relieve symptoms and increase quality of life. In Indonesia, waiting time for getting coronary artery bypass grafting (CABG) procedure for revascularization treatment in stable angina pectoris patients is way longer than international recommendation which correlates with increase morbidity and mortality during the waiting time. Utilization of ECP for such patients who wait for CABG procedure is still unclear. The investigator aim to evaluate efficacy of addition of ECP compared with medical therapy alone for this population. The efficacy is evaluated using measurement from echocardiography result, treadmill test result, and clinical outcome. if applicable, examination of myocardial perfusion using nuclear examination will also be performed.",[381,26],"Counterpulsation",[383,384,385,386,387],"External Counterpulsation","Stable Angina Pectoris","Indicated CABG","Global longitudinal strain","Ischemic response","2023-09-21",{"date":390,"type":42},"2023-09-25",{"date":392,"type":42},"2023-07-01",{"date":246,"type":21},{"name":395,"class":222},"Universitas Padjadjaran"]